Here's Why Regeneron (REGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
REGN - Regeneron Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$840.15
DETAILS
HIGH:
$995.00
LOW:
$641.00
MEDIAN:
$857.50
CONSENSUS:
$840.15
UPSIDE:
31.50%
Stock News
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or cardiac involvement demonstrated improvement in organ function, despite short follow-up First results from the Phase 1/2 LINKER-AL2 trial to be detailed in an ASCO oral presentation; the Phase 2 portion of the trial with registrational intent is ongoing TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2 trial evaluating Lynozyfic® (linvoseltamab) in adults with second-line-plus systemic amyloid light chain (AL) amyloidosis, which will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting on Friday, May 29 at 2:45 p.m.
Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) lost significant market capitalization on May 16, 2026, when the Company disclosed that its Phase 3 melanoma trial of fianlimab combined with Libtayo failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here.
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo i
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
NEW YORK--(BUSINESS WIRE)--Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. During the Q1 2026 e.
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations
Regeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in. NEW YORK, May 19, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw the stock decline more than 10% when the market opened on May 18, 2026 after investors digested the weekend news that Regeneron's Phase 3 melanoma trial of Fianlimab + Libtayo failed to meet its primary endpoint versus Merck's Keytruda (pembrolizumab).
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)
Regeneron's executives were optimistic about the potential for fianlimab + Libtayo; when the study failed to produce exepected results, the stock opened down more than 10%. NEW YORK, May 18, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw significant losses when the stock dropped sharply following the May 16, 2026 disclosure that its Phase 3 melanoma trial of fianlimab + Libtayo failed to meet its primary endpoint versus Keytruda.
Regeneron stock drops double digits on oncology trial failure
Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal late-stage clinical trial. The sharp selloff followed Regeneron's announcement that its high-dose fianlimab and cemiplimab combination failed to significantly outperform Merck's Keytruda in a Phase 3 study involving patients with previously untreated metastatic melanoma.
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky About Fraud Investigation
New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ: REGN) concerning potential violations of the federal securities laws. In March, the Senior Vice President of Investor Relations, Ryan Crowe, told investors management was "hopeful" for the LAG-3 study to show positive differentiators for Fianlimab in combination with Libtayo, such as a low to mid-teens median PFS" and an "opportunity to have a statistically significant, clinically meaningful benefit on OS.
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.
Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today
U.S. equities opened the new trading week on a split footing on Monday as a sharp unwind in AI-infrastructure names dragged the Nasdaq 100 down by over 1%, while energy, communications and insurance shares cushioned the broader market.
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation.
Stock Futures Climb as Investors Monitor Middle East
Stock futures are in the black, with the Dow cautiously higher as investors watch U.S. and Iran
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely watched clinical trial of the year delivered a statistical miss that has prompted a wave of analyst downgrades. The company disclosed on Friday that its phase 3 trial of fianlimab, combined with its approved immunotherapy cemiplimab, as a first-line treatment for advanced melanoma did not reach statistical significance on its primary goal of improving progression-free survival compared with Merck's established cancer drug Keytruda.
Here Are Monday’s Top Wall Street Analyst Research Calls: Applied Materials, CoreWeave, Deckers Outdoor, F5, Lam Research, Salesforce, ServiceNow, Zscaler, and More
Pre-Market Stock Futures: Futures are trading lower after a spectacular week came to an abrupt end Friday, as all the major indices were absolutely hammered. Voices across financial media were busy pointing out that the market is the most expensive based on the Schiller PE (price-to-earnings) metric since the dot-com crash in 2001. Pair that with... Here Are Monday's Top Wall Street Analyst Research Calls: Applied Materials, CoreWeave, Deckers Outdoor, F5, Lam Research, Salesforce, ServiceNow, Zscaler, and More
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Price Targets
Regeneron price target lowered to $875 from $1,057 at Canaccord
$875.00
(was $629.68)
John Newman
·
Canaccord Genuity
Regeneron price target lowered to $860 from $900 at Wolfe Research
$860.00
(was $629.36)
Alexandria Hammond
·
Wolfe Research
Regeneron price target lowered to $825 from $875 at Evercore ISI
$825.00
(was $619.84)
Evercore ISI
Regeneron price target lowered to $707 from $762 at RBC Capital
$707.00
(was $619.62)
RBC Capital
Regeneron price target lowered to $778 from $796 at Truist
$778.00
(was $619.95)
Truist Financial
Regeneron price target lowered to $730 from $900 at BMO Capital
$730.00
(was $698.25)
BMO Capital
Regeneron price target lowered to $855 from $875 at Piper Sandler
$855.00
(was $698.25)
Piper Sandler
Leerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk
$641.00
(was $698.25)
Market Perform
·
Leerink Partners
Regeneron price target raised to $995 from $975 at Guggenheim
$995.00
(was $707.06)
Yatin Suneja
·
Guggenheim
Regeneron price target lowered to $788 from $796 at Morgan Stanley
$788.00
(was $703.18)
Terence Flynn
·
Morgan Stanley
Regeneron price target lowered to $796 from $801 at Truist
$796.00
(was $692.75)
Truist Financial
Regeneron price target lowered to $917 from $923 at Barclays
$917.00
(was $686.36)
Barclays
Raymond James Reiterates Outperform Rating on Regeneron Pharma (REGN)
$910.00
(was $746.58)
Chris Raymond
·
Raymond James
Regeneron price target raised to $796 from $769 at Morgan Stanley
$796.00
(was $746.15)
Morgan Stanley
Regeneron price target lowered to $921 from $925 at Bernstein
$921.00
(was $775.53)
Bernstein
Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) following Ph3 study results
$818.00
(was $770.32)
Greg Renza
·
Truist Financial
Barclays Starts Regeneron Pharma (REGN) at Overweight
$923.00
(was $764.93)
Eliana Merle
·
Barclays
Regeneron Pharma (REGN) PT Raised to $765 at RBC Capital
$765.00
(was $784.06)
Brian Abrahams
·
RBC Capital
Regeneron price target raised to $975 from $865 at Guggenheim
$975.00
(was $785.51)
Guggenheim
Regeneron price target raised to $800 from $740 at Cantor Fitzgerald
$800.00
(was $757.59)
Carter Gould
·
Cantor Fitzgerald